Monday, January 16, 2017 11:44:17 PM
Or it might just be a Jan bounce after tax selling in December. But one way or another, they have to get some money in the coffers. The NIH paid for the Dronabinol Phase 2, so they might agree to help fund the Phase 3. Or the recent Phase 2 results might shake loose some private funds. Likewise, funds will be needed on the Ampakine side. Hopefully Dr. Lippa's connections in the private equity world will come through, or alternately a pharma partner will appear with some cash.
I wonder if RSPI has approached some of the foundations out there, like the Michael Jackson Foundation? As we know, preclinical data shows that Ampakines reverse Propofol induced Respiratory Depression, so an Ampakine could have saved Michael Jackson's life.
Unlike opioids, there is no reversal agent for Propofol. So the only other way to save MJ would have been to put him on an artificial respirator, but for that his doctor 1) would have to be there, 2) notice the lack of breathing, and 3) have a respirator machine present. On the other hand, with an Ampakine you simply administer it with the Propofol and voila, no respiratory depression occurs. Alternately, you administer the Ampakine later and it reverses the respiratory depression after it's started. Propofol overdose also killed Joan Rivers.
Btw, preclinical data also shows that Ampakines prevent/reverse Respiratory Depression from Benzodiazepines (the Valium and Xanax family).
Recent RSPI News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 12:45:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:05:55 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:15:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 12:52:24 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM